Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM CHLORIDE 10% vs MICRO-K
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.
Emergency treatment of hypocalcemic tetany,Cardiac resuscitation in the presence of hyperkalemia or hypocalcemia,Treatment of calcium channel blocker overdose,Treatment of magnesium sulfate overdose,Management of acute hypermagnesemia,Used in cardiac surgery to reverse citrate anticoagulation
Treatment of hypokalemia,Prevention of hypokalemia in patients at risk (e.g., on diuretics, digitalis)
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.
Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
Not applicable; potassium is an electrolyte with no true elimination half-life; whole-body turnover half-life is approximately 12-24 hours, clinically relevant for dosing intervals.
Calcium chloride is not metabolized; it is excreted primarily in the urine with reabsorption regulated by the kidneys and parathyroid hormone.
Potassium ions are not metabolized; they are primarily excreted unchanged by the kidneys (90%), with minor losses via feces and sweat.
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
Renal: approximately 90% of absorbed potassium is excreted in urine; biliary/fecal: less than 10% eliminated via feces.
Approximately 45-50% bound to albumin; 10-15% complexed with citrate, phosphate, or bicarbonate.
None; potassium is not significantly bound to plasma proteins.
0.3-0.4 L/kg (primarily extracellular fluid). Increased in hypocalcemia or hypoalbuminemia.
0.5-0.7 L/kg; total body water distribution; clinically indicates extensive intracellular uptake (98% intracellular).
IV/IO: 100%. Not administered orally for systemic effect due to GI irritation and poor absorption; oral bioavailability is negligible (<1%) if ingested.
Oral: approximately 80-90% for Micro-K (extended-release); absorption occurs in small intestine.
e GFR <30 m L/min: Use with caution, reduce dose by 50% and monitor serum calcium closely; e GFR <15 m L/min: Avoid use if possible, if necessary use lowest effective dose with frequent monitoring.
e GFR ≥60 m L/min: No adjustment. e GFR 30-59: Reduce dose by 25-50% and monitor potassium. e GFR 15-29: Reduce dose by 50-75% and monitor potassium. e GFR <15: Avoid use or use with extreme caution; maximum 20 m Eq/day with frequent monitoring.
No specific dose adjustment required for Child-Pugh class A, B, or C; monitor serum calcium due to potential for altered vitamin D metabolism.
No specific dosing adjustments recommended for hepatic impairment. Monitor potassium levels as hepatic disease may affect potassium homeostasis.
IV: 10-20 mg/kg of elemental calcium (0.1-0.2 m L/kg of 10% solution) given slowly (not exceeding 0.5 m L/min). Maximum single dose: 500 mg (5 m L). May repeat in 4-6 hours if needed.
Oral: <1 year: 1-2 m Eq/kg/day divided 2-4 times. 1-18 years: 1-3 m Eq/kg/day divided 2-4 times; maximum 100 m Eq/day. Extended-release capsules not recommended for children unable to swallow whole capsules.
Start at lower end of dosing range (e.g., 500 mg IV), administer at a slower rate (over 10-15 minutes) due to higher risk of hypercalcemia and cardiovascular effects; monitor renal function and serum calcium frequently.
Start at low end of dosing range (20-40 m Eq/day) due to decreased renal function; maximum 100 m Eq/day. Monitor renal function and potassium levels closely.
Rapid intravenous injection may cause cardiac arrest. Avoid extravasation as it causes severe tissue necrosis. Use with extreme caution in patients receiving digitalis glycosides due to risk of arrhythmias.
None
Administer intravenously only; intramuscular or subcutaneous injection causes severe irritation and necrosis.,Use with caution in patients with renal impairment, sarcoidosis, or hypercalcemia.,Monitor serum calcium levels and electrocardiogram during administration.,Risk of bradycardia and arrhythmias, especially with concurrent digitalis therapy.,Rapid injection may cause vasodilation, hypotension, and cardiac arrest.
Hyperkalemia risk, especially in patients with renal impairment, diabetes, or those receiving potassium-sparing diuretics, ACE inhibitors, or ARBs,Suspect gastrointestinal obstruction or perforation with slow-release formulations; caution in patients with severe GI disorders,Use with caution in patients with cardiac disease, particularly those on digoxin,Monitor serum potassium levels regularly
Hypercalcemia,Ventricular fibrillation during cardiac arrest (unless due to hypocalcemia),Severe hypercalciuria or calcinosis,Concurrent digitalis therapy (relative, may increase risk of arrhythmias)
Hyperkalemia (serum potassium >5.5 m Eq/L),Renal failure or severe renal impairment (e.g., oliguria, anuria),Addison's disease,Acute dehydration,Concomitant use with potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene),Concomitant use with eplerenone,Solid dosage forms in patients with delayed gastric emptying or esophageal compression
Avoid excessive intake of oxalate-rich foods (spinach, rhubarb, beets) and phytate-rich foods (bran, whole grains) as they may bind calcium and reduce absorption. Also limit sodium-containing foods to prevent calcium loss via urine. No direct food interactions with intravenous administration.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes) and potassium-based salt substitutes. Consuming large amounts of these may increase risk of hyperkalemia.
Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calcium is an essential mineral for fetal development; however, high doses may lead to hypercalcemia in the mother and fetus. In the first trimester, no specific teratogenic risk is documented; however, maternal hypercalcemia from excessive supplementation may interfere with placental calcium transport and fetal bone development. In the second and third trimesters, excessive doses may cause fetal hypoparathyroidism, hypercalcemia, and potential neonatal hypocalcemia due to suppression of the fetal parathyroid gland. Use only if clearly needed and with caution.
Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperkalemia may increase risks. No trimester-specific risks documented.
Calcium is excreted into breast milk. The M/P ratio for calcium is approximately 1.0 (range 0.9-1.1) reflecting passive diffusion and active transport. Intravenous calcium chloride administration may transiently increase maternal serum calcium levels, leading to a small increase in milk calcium concentration. However, this is unlikely to cause adverse effects in the breastfed infant. The American Academy of Pediatrics considers calcium supplementation compatible with breastfeeding. Use with caution and monitor infant for signs of hypercalcemia (e.g., constipation, irritability) if high doses are administered.
Potassium is a normal constituent of breast milk. Supplemental potassium does not affect milk potassium content. M/P ratio not applicable. Use with caution if maternal renal function impaired.
Pregnancy is associated with increased plasma volume and enhanced renal clearance, potentially lowering serum calcium levels. However, calcium chloride is typically administered intravenously for acute hypocalcemia or cardiac resuscitation; no specific dose adjustments are recommended solely due to pregnancy. Use standard dosing based on the indication and severity of hypocalcemia, with close monitoring of serum calcium to avoid overdosage. The same caution applies: administer slowly (0.5-1 m L/min of 10% solution) and check ECG if rapid infusion.
No standard dose reduction required. Pharmacokinetic changes in pregnancy (increased GFR, blood volume) may increase potassium requirements or decrease serum levels; monitor and adjust dose to maintain normal serum potassium (3.5-5.0 m Eq/L).
Calcium chloride 10% (100 mg/m L) provides 13.6 m Eq/10 m L of calcium. It is highly irritating; administer via central venous line to avoid severe tissue necrosis if extravasation occurs. Do not mix with bicarbonate or phosphate solutions. In cardiac arrest, consider dose of 500-1000 mg IV push (repeat q10min if needed). Contraindicated in digitalis toxicity due to risk of fatal arrhythmias.
Micro-K (potassium chloride extended-release) is used to prevent and treat hypokalemia. Avoid use in severe renal impairment, metabolic acidosis, or conditions with high potassium levels. Slow-release formulations reduce GI irritation but may be contraindicated in patients with GI motility disorders. Do not crush or chew capsules; administer with food and a full glass of water. Monitor serum potassium and renal function regularly.
This medication is given intravenously to treat calcium deficiency or certain emergencies.,You may experience a warm sensation, metallic taste, or flushing during injection.,Report any burning, pain, or redness at the injection site immediately.,Avoid taking digoxin (digitalis) unless specifically instructed by your doctor.,Do not stop or change the dose without consulting your healthcare provider.
Take this medication with food and a full glass of water to reduce stomach upset.,Swallow the capsule whole; do not crush, chew, or open it.,Do not suddenly stop taking this medication without consulting your doctor.,Avoid salt substitutes or potassium-containing supplements unless approved by your doctor.,Seek immediate medical attention if you experience signs of high potassium levels: muscle weakness, irregular heartbeat, or tingling in hands/feet.
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM CHLORIDE 10% vs MICRO-K, answered by our medical review team.
CALCIUM CHLORIDE 10% is a Electrolyte Supplement that works by Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.. MICRO-K is a Electrolyte Supplement (Potassium) that works by Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM CHLORIDE 10% and MICRO-K depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM CHLORIDE 10% is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.. The standard adult dose of MICRO-K is: Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM CHLORIDE 10% and MICRO-K in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM CHLORIDE 10% is classified as Category C. Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calc. MICRO-K is classified as Category C. Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.